Drugs Made In America Acquisition II Corp. (DMII) Stock Price & Analysis
Drugs Made In America Acquisition II Corp. (DMII) closed at USD 10.19 on Thursday, October 15, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 10.19; the Oct 15, 2026 session ranged USD 10.18–10.19 on volume of 121,799 shares. Market capitalization is $649.10M, with a 52-week range of USD 9.86–10.33 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DMII.md
Key facts (DMII)
- Analysts: None.
- Total return with dividends: 1Y +3.1% vs S&P 500 +18.1%; 5Y +3.1% vs S&P 500 +85.1%.
Analysts (DMII)
Consensus None.
Total return (dividends reinvested) (DMII)
| 1Y (from 2025-12-03) | 5Y (from 2025-12-01) | |
|---|---|---|
| Total return | +3.1% | +3.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 1.8% | 1.4% |
| Max drawdown | -0.7% (Feb 2026→Mar 2026) | -0.5% (Feb 2026→Mar 2026) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 10.19 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 10.19 |
| Open | USD 10.19 |
| Day Range | USD 10.18 – 10.19 |
| 52-Week Range | USD 9.86 – 10.33 |
| Volume | 121,799 shares |
| Market Cap | $649.10M |
| Exchange | NGM |
Technical Analysis (DMII)
Nexqual's technical model rates DMII "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 65.57 (neutral) |
| vs SMA50 | Above (USD 10.16) |
| MACD | 0.01 (positive) |
Analyst Ratings (DMII)
Wall Street analysts rate DMII "None", per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | None |
|---|
Earnings (DMII)
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (DMII)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.34 |
| Total Cash | $174,974 |
| Total Debt | $450,000 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (DMII)
Nexqual rates Drugs Made In America Acquisition II Corp.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $175K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$1M (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — No data |
Ownership (DMII)
| Insider Ownership | +15.21% |
|---|---|
| Institutional Ownership | +72.88% |
| Shares Outstanding | 63.70M |
| Float | 54.01M |
| Short % of Float | +0.20% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (DMII)
Drugs Made In America Acquisition II Corp. is led by Roger Bendelac (age 68), Chief Executive Officer, per Nexqual as of October 16, 2026 at 05:22 UTC.
| Chief Executive Officer | Roger Bendelac (age 68) |
|---|---|
| CFO & Principal Accounting Officer | Saleem Elmasri (age 38) |
Major Backers & Investors (DMII)
Notable institutional backers of Drugs Made In America Acquisition II Corp. include Karpus Management, Inc., MMCAP International, Inc. SPC, Magnetar Financial LLC, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Karpus Management, Inc. | 4.38% |
| MMCAP International, Inc. SPC | 4.24% |
| Magnetar Financial LLC | 4.24% |
| Glazer Capital LLC | 3.68% |
| Highbridge Capital Management, LLC. | 3.52% |
| Millennium Management | 3.13% |
| Hudson Bay Capital Management Lp | 3.09% |
| Wolverine Asset Management, LLC | 2.91% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CCXI | Churchill Capital Corp XI | USD 11.35 | ▲ 1.7% |
| EVAC | EQV Ventures Acquisition Corp. | USD 10.3 | ▼ 0.1% |
| BCSS | Bain Capital GSS Investment Cor | USD 10.22 | ▼ 0.15% |
| CEPF | Cantor Equity Partners IV, Inc. | USD 10.26 | ▼ 0.24% |
| AEXA | American Exceptionalism Acquisi | USD 10.8 | ▼ 0.92% |
| XRPN | Evernorth Holdings Inc. | USD 16.07 | ▼ 2.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt